Egis Atorvastatin - Dapagliflozin Egis Atorvastatin - Dapagliflozin

X

Find Drugs in Development News & Deals for Atorvastatin

PharmaCompass
API SUPPLIERS
API Suppliers

API Suppliers

US DMFs Filed

US DMFs Filed

CEP/COS Certifications

CEP/COS Certifications

JDMFs Filed

JDMFs Filed

Other Certificates

Other Certificates

Other Suppliers

Other Suppliers

API REF. PRICE (USD / KG)
205
INTERMEDIATES
DOSSIERS // FDF
USA (Orange Book)

USA (Orange Book)

Europe

Europe

Canada

Canada

Australia

Australia

South Africa

South Africa

Uploaded Dossiers

Uploaded Dossiers

GLOBAL SALES (USD Million)

U.S. Medicaid

Annual Reports

EXCIPIENTS
PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

USFDA Exclusivities

0

DIGITAL CONTENT

Blog #PharmaFlow

News

REF STANDARD

EDQM

USP

JP

Other Listed Suppliers

SERVICES
left grey arrow
right gray arrow
  • TABLET;ORAL - EQ 10MG BASE;10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
  • TABLET;ORAL - EQ 20MG BASE;10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
  • TABLET;ORAL - EQ 40MG BASE;10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
  • TABLET;ORAL - EQ 80MG BASE;10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
  • TABLET;ORAL - EQ 10MG BASE
  • TABLET;ORAL - EQ 20MG BASE
  • TABLET;ORAL - EQ 40MG BASE
  • TABLET;ORAL - EQ 80MG BASE
  • TABLET;ORAL - EQ 10MG BASE;EQ 10MG BASE
  • TABLET;ORAL - EQ 10MG BASE;EQ 20MG BASE
  • TABLET;ORAL - EQ 10MG BASE;EQ 40MG BASE
  • TABLET;ORAL - EQ 10MG BASE;EQ 80MG BASE
  • TABLET;ORAL - EQ 2.5MG BASE;EQ 10MG BASE
  • TABLET;ORAL - EQ 2.5MG BASE;EQ 20MG BASE
  • TABLET;ORAL - EQ 2.5MG BASE;EQ 40MG BASE
  • TABLET;ORAL - EQ 5MG BASE;EQ 10MG BASE
  • TABLET;ORAL - EQ 5MG BASE;EQ 20MG BASE
  • TABLET;ORAL - EQ 5MG BASE;EQ 40MG BASE
  • TABLET;ORAL - EQ 5MG BASE;EQ 80MG BASE

Details:

Atorvaliq (atorvastatin calcium) is the first and only FDA-approved oral liquid Suspension that is indicated for the treatment of high cholesterol and certain risk factors for heart disease or stroke.


Lead Product(s): Atorvastatin

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Atorvaliq

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 23, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Apabetalone (RVX000222), is a first-in-class, small molecule, therapeutic candidate with an epigenetic mechanism of action. It is a BD2 (bromodomain) selective BET (bromodomain and extra-terminal) inhibitor that works in preventing and treating disease progression.


Lead Product(s): Apabetalone,Atorvastatin,Rosuvastatin

Therapeutic Area: Endocrinology Product Name: RVX000222

Highest Development Status: Phase IIIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 22, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Treatment with TA-8995 (obicetrapib) in patients on high-intensity statin therapy was observed to have statistically significant impact on LDL-C, as well as significant impacts on ApoB, non-HDL-C, HDL-C and Lp(a), additional key measures of cardiovascular disease risk.


Lead Product(s): Obicetrapib,Atorvastatin

Therapeutic Area: Cardiology/Vascular Diseases Product Name: TA-8995

Highest Development Status: Phase IIIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Frazier Healthcare Partners

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 11, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Astellas and Viatris have agreed to end the co-promotion of a hypercholesterolemia and familial hypercholesterolemia treatment “Lipitor® Tablets 5mg, 10mg” manufactured and sold by Astellas.


Lead Product(s): Atorvastatin

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Lipitor

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Astellas Pharma

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Termination April 01, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The aim of this Phase 2 study was to evaluate LDL-C lowering when NEXLETOL was initiated together with ezetimibe (10 mg) and atorvastatin (20 mg), as compared with placebo.


Lead Product(s): Bempedoic Acid,Ezetimibe,Atorvastatin

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Nexletol

Highest Development Status: Phase IIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 17, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The U.S. Patent covers pharmaceutical compositions comprising a statin and a cannabinoid, and their use for the treatment of hypercholesterolemia and atherosclerosis.


Lead Product(s): Atorvastatin,Cannabidiol

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

Highest Development Status: PreclinicalProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 01, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Pfizer and Mylan have received clearance from the US FTC to advance the merger of Pfizer’s Upjohn generics unit and Mylan. As part of the FTC clearance, the companies need to divest seven products before moving forward with the merger, this includes Upjohn’s Caduet.


Lead Product(s): Amlodipine,Atorvastatin

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Caduet

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Viatris

Deal Size: $12,000.0 million Upfront Cash: Undisclosed

Deal Type: Merger November 16, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The FDA has accepted Resverlogix BETonMACE2 clinical plan as a registration enabling study with positive implications for Resverlogix and its ongoing partnership discussions.


Lead Product(s): Apabetalone,Atorvastatin

Therapeutic Area: Endocrinology Product Name: RVX000222

Highest Development Status: Phase IIIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 22, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

For the first time in patients with a recent Acute Coronary Syndrome with diabetes and stage 3 CKD co-morbidities, we observed a 50% reduction of MACE by a medication, apabetalone treatment.


Lead Product(s): Apabetalone,Atorvastatin

Therapeutic Area: Endocrinology Product Name: Undisclosed

Highest Development Status: Phase IIIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 09, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Apabetalone recently completed the first ever Phase 3 clinical trial of a BET inhibitor for a cardiovascular disease indication.


Lead Product(s): Apabetalone,Atorvastatin

Therapeutic Area: Endocrinology Product Name: Undisclosed

Highest Development Status: Phase IIIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 30, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY